On July 16th, Gralon announced that Biotie Therapies Corp. (02315.HK) has reached a research collaboration and exclusive option and license agreement with SOTIO Biotech. Accordingly, SOTIO has been granted an option to obtain a license to use a variety of fully human bispecific antibodies generated using Biotie's proprietary RenLite platform, which SOTIO will use to develop the next generation of antibody-drug conjugates (ADCs) targeting solid tumors. The agreement also includes an option for SOTIO to use Biotie's proprietary ADC platform. Under the terms of the agreement, Biotie has the right to receive upfront and potential milestone payments of up to $325.5 million, as well as low single-digit percentage royalties on net sales. SOTIO and Biotie will collaborate closely during the bispecific project research phase, with SOTIO responsible for non-clinical and clinical development, production and commercialization of ADC products.
SOTIO is shaping the future of targeted cancer therapy by translating convincing science into patient benefit. SOTIO's product pipeline includes three clinical-stage programs: SOT102, a next-generation antibody-drug conjugate targeting Claudin-18.2; BOXR1030, a metabolic-enhanced CAR-T cell therapy targeting GPC3-expressing tumors; and SOT201, a next-generation immune cytokine targeting PD-1. SOTIO is a member of the PPF Group. SOTIO is a registered trademark of SOTIO Biotech a.s. in certain countries.
